Immunotherapy plus chemo for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests adding immunotherapy drugs (PD-1 or PD-L1 inhibitors) to standard chemotherapy, with or without bevacizumab, for people with cervical cancer that has spread, persisted, or come back after treatment. The goal is to see which combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have cervical cancer that has spread to other parts of the body (metastatic), has not been cured after initial treatment (persistent), or has come back after treatment (recurrent).
- You have a tissue sample available to test for a protein called PD-L1 (needed for immunotherapy).
- You are able to do most daily activities without help (ECOG score 0 or 1).
- You do not have another active cancer, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that combines an immunotherapy drug (cadonilimab) with chemotherapy for people with locally advanced cervical cancer. The goal is to see if this combination can shrink the tumor enough to make surgery possible or more effective.
This Phase 3 study tests GLS-010 added to standard platinum chemotherapy, with or without bevacizumab, as a first treatment for cervical cancer that has persisted, come back, or spread. If you have PD-L1–positive tumors, the goal is to improve how long people can control the cancer compared with standard chemotherapy alone.
This trial tests combining standard chemoradiation with a PD-1 inhibitor (a drug that helps your immune system fight cancer) for advanced cervical cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatment alone.
This trial tests combining two immunotherapy drugs with chemotherapy and sometimes another drug called bevacizumab, followed by radiation and chemotherapy. It aims to see if this approach can better treat advanced cervical cancer.
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
This trial tests whether combining chemotherapy with immunotherapy before surgery can help treat cervical cancer that is PD-L1 negative. It's for women with larger tumors (stage IB3 to IIB) who have not been treated yet.
Hear when a new Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.